In summary, IL-18 plays a pivotal role in the immunological enhancement of CAR-T cell therapy, promoting both direct anti-tumor activity and the recruitment of additional immune effectors, thereby improving therapeutic outcomes in cancer immunotherapy. Here, IL18 is linked to neoplasm.